Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lung Neoplasms × X-Rays × Clear all

Phase

Phase NA 16 Phase 1 4 Phase 2 2 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinosarcoma 2 Brain Neoplasms 2 Wilms Tumor 1 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors 1 Lung Neoplasms 1 Locally Advanced Cervical Adenocarcinoma 1 Liposarcoma 1 Histiocytoma, Malignant Fibrous 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Burkitt Lymphoma 1 Barrett Esophagus 1 Anus Neoplasms 1 Anal Canal Carcinoma 1 Adenoma, Islet Cell 1

Interventions

Carboplatin 66 Cisplatin 57 Paclitaxel 42 Radiotherapy 35 Pemetrexed 34 Gemcitabine 31 Docetaxel 31 Etoposide 24 pembrolizumab 21 Vinorelbine 20 Erlotinib Hydrochloride 13 Magnetic Resonance Spectroscopy 12 Gefitinib 11 Specimen Handling 10 Radiosurgery 10 Drug Therapy 10 Bevacizumab 10 durvalumab 9 Nivolumab 9 Vinblastine 6 Topotecan 6 Surgical Procedures, Operative 6 Cyclophosphamide 6 Standard of Care 5 Platinum 5 Immunoglobulin G 5 Ifosfamide 5 Disulfides 5 Dexamethasone 5 paclitaxel poliglumex 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499674 2026-03-30

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡